Pathologically Scarred by Fibrosis: How To Model and Quantify Human NASH in a Microphysiological System
Who's speaking at this Webinar?
Dr Gareth Guenigault
Senior Scientist, CN Bio Innovations
Dr Samantha Peel
Principal Scientist, Functional Genomics, Discovery Sciences, AstraZeneca
Non-alcoholic steatohepatitis (NASH) is a widespread disease affecting up to ~12% of the US population – characterized by lipid accumulation in hepatocytes, infiltration of immune cells and fibrosis of the liver. Replicating liver fibrosis is a key element in any in vitro NASH model, however, it is normally poorly assessed, unquantifiable and has a limited dynamic range.
An advanced three-dimensional (3D) microfluidic NASH model has been developed using primary human cells to replicate the human biomarkers of the disease. In this webinar, we will demonstrate how the model can be fine-tuned using exogenous stimuli to enhance key features such as fibrosis or inflammation. We will furthermore discuss the development of an automated workflow to acquire and analyze confocal fluorescent images of these 3D microtissues in order support characterization of fibrosis.
Attend this webinar to learn about:
- Developing an in vitro 3D microfluidic NASH model
- Effects of exogenous stimuli on NASH (e.g., TGFβ, lipopolysaccharides, fructose, cholesterol)
- Characterizing fibrosis using confocal microscopy
- Automation of confocal imaging in a 3D in vitro model
Like what you just read? You can find similar content on the communities below.
Biopharma Drug DiscoveryTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
